Alfredo Sanchez-Hernandez on Muck Rack

Alfredo Sanchez-Hernandez

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alfredo

Contact Alfredo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial

|
By Jaume Capdevila, Jorge Hernando, María Plana Serrahima, Beatriz Castelo, Cristina Álvarez-Escola, Alberto Carmona-Bayonas, Inmaculada Navarro, Lara Romero Iglesias, Mateo Bover, Alejandro Garcia-Alvarez, Javier Lavernia, Sofia Ruiz, Sofía Ruiz, Neus Basté, Enrique Sanz-Garcia, Gloria Marquina, Paolo Nuciforo, Enrique Grande, Teresa Alonso-Gordoa, Javier Molina-Cerillo, Miren Taberna Sanz, Ricardo Yayá Tur, Isabel Lorenzo-Lorenzo, Alfredo Sanchez-Hernandez, Belén Elguero
| Nature
Abstract Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer.
Open in Who Shared Issue with article?
See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Alfredo

Contact Alfredo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified